ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Goldstream Investment Limited: Proposed Strategic Acquisition of Three High-quality Assets

HONG KONG SAR - Media OutReach Newswire - 3 July 2024 - Goldstream Investment Limited (stock code: 1328.HK) announced that on 28 June 2024 its wholly-owned subsidiaries and the wholly-owned subsidiaries of Hony Capital Group Limited signed three respective agreements, including Feasible Result agreement, USFL agreement and TechStar agreement, and proposed to acquire three high-quality assets of Hony Capital Group Limited at a total acquisition consideration of approximately US$38 million.

The consideration for shares for sale of Feasible Result is US$26 million. Upon the completion of the transaction, Goldstream Investment Limited will indirectly own 30% of Feasible Result. Feasible Result indirectly owns 100% equity interest in Shanghai Li Fung, which is in turn the registered owner of LiFung Plaza. LiFung Plaza was jointly built by Fung Holdings (1937) Limited and Hony Capital Group Limited, which is located in the core area of the Shanghai science and technology innovation hub - Caohejing Hi-Tech Park, and the park's positioning fully fits with Shanghai's plan to build a "3+6" new industrial system. It has transformed into a vibrant community centered around the AI and fashion industries, drawing in a cluster of technology and new economy companies to settle in.

The consideration for shares for sale of USFL is US$5 million. Upon the completion of the transaction, Goldstream Investment Limited will indirectly own 32% of USFL. The sole assets of USFL will be 908,000 Advaccine Shares and USFL will not have any liabilities. Advaccine is a leading biotechnology enterprise incorporated in China, the shares of which were listed and traded on the NEEQ in February 2023 (stock code: 874055). The principal business activities of Advaccine are to develop and produce innovative vaccines and drugs based on its antigen technology platform, adjuvant technology platform and drug delivery technology platform. The RSV vaccine developed by Advaccine is one of the fastest developing products in China and is expected to complete phase II clinical trials by 2024.

The total consideration for shares for sale and warrants for sale of TechStar is US$6.877 million. TechStar is a special purpose acquisition company (SPAC) listed in the Stock Exchange of Hong Kong focusing on the acquisition of high-growth companies in the "new economy" sector in China (stock and warrant codes are 7855 and 4855, respectively). The successful De-spac Transaction will provide TechStar with potential value growth opportunities.

The Directors of Goldstream Investment Limited (excluding the independent non-executive directors) believe that the strategic acquisition assets were carefully selected from the existing investments of Hony Capital Group Limited, with high quality and favourable terms, which can effectively improve the capital base and market capitalization of Goldstream Investment Limited. In the future, shareholders can expect further high-quality asset injections by Hony Capital Group Limited on favorable terms, which is conducive to the share price and market performance of Goldstream Investment Limited.

Hashtag: #GoldstreamInvestment

The issuer is solely responsible for the content of this announcement.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.